Best Euronext Stocks to Buy Today (5 December 2025): 8 Ideas With Fresh Catalysts

European stocks are grinding higher into year‑end, and Euronext’s main benchmarks are hovering near the top of their 52‑week ranges. The Euronext 100 index closed around 1,712 points on 5 December 2025, up roughly 17% over the last 12 months and not far from its record high. ^[1]

At the same time, macro sentiment is supportive: the pan‑European STOXX 600 is up again today, with autos, industrials and basic resources benefitting from sector upgrades and hopes of a 2026 fiscal boost, while investors wait for key U.S. inflation data and a likely Fed rate cut. ^[2]

Below is a non‑exhaustive list of eight Euronext‑listed stocks that stand out today based on fresh news, updated guidance and structural themes. This is educational information, not investment advice; always do your own research and consider speaking to a licensed adviser before buying any stock.

How these “best Euronext stocks” were picked

For 5 December 2025, the focus is on:

Very recent news or guidance, ideally in the last few days.
Clear catalysts (buybacks, guidance upgrades, new leadership, strategic plans).
Reasonably strong fundamentals (revenue growth, margins, balance sheet strength or cash returns).
Sector diversification across autos, consumer staples, biopharma, exchanges, tech and health tech.

All of these companies are listed on Euronext markets (Paris, Amsterdam, Brussels, Milan, etc.), even if they also trade in New York or elsewhere.

1. Stellantis N.V. (STLAM / STLAP) – Autos with high cash returns and strong Q3

Stellantis, the maker of Peugeot, Citroën, Opel, Jeep and more, is one of the most widely traded names on Euronext Milan and Euronext Paris. It combines cyclical upside with a hefty dividend and aggressive capital returns.

Why Stellantis looks interesting today

Fresh news today (5 Dec): the company reported that its “Shares to Win” employee share purchase plan has now reached 22 million shares subscribed since 2023, with employees collectively holding 2.8% of the company’s capital. The 2025 edition spanned 20 countries, with an average employee investment above €1,150. ^[3]
- This kind of broad‑based ownership tends to align employees with shareholders and supports long‑term value creation.
Q3 2025 performance: Stellantis posted net revenues of €37.2 billion, up 13% year‑on‑year, and a 13% increase in shipments to 1.3 million units. Growth was driven by North America, “Enlarged Europe” and the Middle East & Africa. ^[4]
The company has announced a $13 billion U.S. investment plan over the next four years to ramp capacity, launch new vehicles and support its hybrid and EV strategy. ^[5]

On top of this, Stellantis trades on a very high dividend yield – close to 8% based on 2025 distributions, according to independent data providers, underlining the stock’s income appeal. ^[6]

Key risks

It’s not all rosy:

French production is forecast to fall around 11% by 2028, reflecting weaker European demand and capacity adjustments at several plants. ^[7]
Stellantis is heavily exposed to the economic cycle, regulation (emissions rules, EV incentives) and competition from both legacy and Chinese carmakers.

Who might consider it: Investors comfortable with cyclical risk who want high cash returns and exposure to a consolidating global auto champion.

2. Heineken N.V. (HEIA) – Premium beer, reshaped leadership and ongoing buybacks

Heineken is a core Euronext Amsterdam name and a global leader in premium and non‑alcoholic beer.

What’s new on 5 December 2025

Today, Heineken announced the appointment of Alex Carreteiro as Regional President Americas, effective 1 March 2026, joining the executive team. Carreteiro previously doubled the size of PepsiCo’s Brazil & South Cone Foods business and has deep emerging‑market and beverages experience. ^[8]
- The Americas are a critical growth region under Heineken’s “EverGreen” strategy, so this hire is a meaningful catalyst.
The company is in the middle of a €1.5 billion share buyback programme; in the first €750m tranche, it had repurchased more than 8.19 million shares by late November. ^[9]

Fundamentals and outlook

In its Q3 2025 trading update, management acknowledged a challenging quarter but still expects full‑year organic operating profit growth towards the lower end of its 4–8% guidance, supported by €0.5 billion gross savings and ongoing premiumisation. ^[10]

Risks: Beer volumes remain sensitive to consumer confidence and pricing, and competition from local brands is intense in emerging markets.

Who might consider it: Investors looking for defensive cash flows, solid brands and steady buybacks with a long‑term EM growth story.

3. Danone S.A. (BN) – Defensive staple plus fresh buyback starting today

Danone, a blue‑chip on Euronext Paris, is a global player in dairy, plant‑based, waters and specialised nutrition.

Today’s direct catalyst (5 December)

On 4 December 2025, Danone announced a buyback of about 3.8 million shares to offset the dilutive impact of employee share plans and long‑term incentives.
The purchase period starts today, 5 December 2025, and will run over the coming weeks, with repurchased shares allocated to employee shareholding plans. ^[11]

Underlying business trends

Q3 2025 sales came in at €6.88 billion, up 4.8% like‑for‑like, driven primarily by 3.2% volume/mix growth and modest pricing. Europe grew 2.6% LFL, China/North Asia & Oceania an impressive 13.8% LFL. ^[12]
For 2025, Danone reaffirmed guidance for 3–5% like‑for‑like sales growth with recurring operating income growing faster than sales. ^[13]

Danone also benefits from a B Corp global certification and positions itself as a health‑focused, ESG‑friendly consumer staple. ^[14]

Risks: Growth in North America has been softer; FX headwinds from emerging‑market currencies and changing consumer trends (e.g., plant‑based slowdown) can affect performance.

Who might consider it: More conservative investors seeking defensive, cash‑generative exposure with a mild buyback tailwind.

4. UCB SA (UCB) – Biopharma name with upgraded 2025 guidance

Belgian biopharmaceutical group UCB, listed on Euronext Brussels, is one of today’s stand‑out movers.

Fresh guidance upgrade driving the move

UCB shares have jumped sharply today, topping Belgium’s BEL 20 index after the company raised its 2025 outlook. ^[15]
It now expects 2025 revenue to exceed €7.6 billion, up from a prior view of more than €7 billion – roughly 4% ahead of previous guidance, according to Investing.com. ^[16]
The company also sees its adjusted EBITDA margin above 31%, compared with “at least 30%” previously, signalling stronger operating leverage as key drugs ramp up. ^[17]

The upgrade is largely attributed to higher demand for newer medicines such as the psoriasis treatment Bimzelx, which has been steadily gaining adoption. ^[18]

Risks: As with all biopharma companies, UCB faces pipeline, patent and pricing risks, as well as regulatory uncertainty.

Who might consider it: Growth‑oriented investors comfortable with healthcare risk, looking for earnings momentum supported by guidance upgrades.

5. ASML Holding N.V. (ASML) – Euronext tech champion riding AI and EUV demand

ASML, a cornerstone of Euronext Amsterdam, is the world’s dominant supplier of advanced lithography equipment for chipmakers—arguably the single most important hardware vendor in the semiconductor value chain.

6. Euronext N.V. (ENX) – The exchange itself, with buyback and strategic expansion

If you want to invest in the health of European capital markets themselves, Euronext, now a member of the CAC 40, is the direct play. ^[24]

Q3 2025 performance and capital allocation

For Q3 2025, Euronext reported revenue and income of €438.1 million, up 10.6% year‑on‑year, and an adjusted EBITDA of €276.7 million, with a 63.2% margin. ^[25]
Net debt to EBITDA dropped to 1.5x at the end of September, from 1.8x in June, underscoring a rapidly deleveraging balance sheet. ^[26]
The company has launched a share repurchase programme of up to €250 million (around 2% of share capital)running from 18 November 2025 to 31 March 2026. ^[27]

Strategically, Euronext is:

Expanding into fixed‑income derivatives with mini‑futures on European government bonds.
Building Euronext ETF Europe, a fully integrated ETF/ETP marketplace.
Pursuing a voluntary share exchange offer for the Athens Stock Exchange (ATHEX), furthering its role in European market consolidation. ^[28]

Risks: Trading and listing revenues are sensitive to market volatility and IPO cycles, and corporate actions such as acquisitions (e.g., ATHEX) carry integration and regulatory risk.

Who might consider it: Investors who want leveraged exposure to European capital markets, trading volumes and ETF growth, with a dividend and buyback kicker.

7. Royal Philips (PHIA) – A contrarian health‑tech idea after a sharp sell‑off

Philips, listed on Euronext Amsterdam, is a major health‑technology player in imaging, monitoring, ultrasound and home health.

What just happened

On 4 December 2025, Philips shares fell more than 6%, making it the worst performer on Amsterdam’s AEX index, after a Citi note suggested the company is unlikely to hit the 4.5% organic growth rate the market expected for 2026. ^[29]
At a conference, management indicated that organic sales growth is expected to improve from about 2% this year into 2026, but perhaps not to consensus levels; tariff headwinds in 2026 are also expected to almost double. ^[30]

Management’s response and medium‑term plan

Philips quickly issued a clarification, reiterating that it will publish its 2026 outlook on 10 February 2026 as planned and still expects sequential comparable sales growth, expanding margins and strong cash flow, with growth accelerating toward mid‑single digits by 2026. ^[31]

This leaves Philips in an interesting spot: execution risk is clearly present, but expectations have just been reset lower, and the company is leaning on a solid installed base and recurring service revenue.

Risks: Litigation and regulatory overhang from past product issues, sensitivity to hospital capex cycles, and the possibility that growth remains sub‑par if execution slips.

Who might consider it: More adventurous investors comfortable with turnaround and sentiment risk, looking for a potential rebound after a sharp de‑rating.

8. Bonus theme: European industrials and autos upgraded for 2026

Even beyond these individual names, the sector backdrop on Euronext is becoming more favourable:

Citi has set a 2026 target of 640 for the STOXX 600 and upgraded autos, industrials, chemicals and basic resources, citing expected fiscal support in 2026. ^[32]
J.P. Morgan has recently upgraded Schneider Electric and other industrial names, helping drive outperformance in the sector. ^[33]

While not analysed in detail here, Euronext‑listed industrial and auto leaders such as Schneider Electric (SU.PA), Airbus (AIR.PA) or selected cyclicals within the CAC 40 and AEX are worth putting on a watchlist if you buy into the 2026 European re‑acceleration story.

How to build your own short‑list of Euronext stocks

If you’re screening Euronext opportunities beyond the eight names above, you might:

Start from the Euronext 100 index, which has climbed about 16.8% over the last year and sits near the upper end of its 52‑week range, indicating broad strength. ^[34]
Filter for:
- Recent, price‑sensitive news (guidance changes, CEO moves, big capex or M&A, buybacks).
- Balance sheet strength, especially net debt/EBITDA and interest coverage.
- Cash returns (dividends + buybacks) that are sustainable, not just one‑offs.
- Sector fit with your macro view (e.g., are you more bullish on defensives like Danone/Heineken, or cyclicals like Stellantis and industrials?).

Always consider:

Diversifying across countries and sectors within Euronext.
Using limit orders and thinking in terms of multi‑year holding periods, not day‑trades.
Stress‑testing your portfolio for different macro scenarios (recession, rate cuts, commodity shocks).

Final word

As of 5 December 2025, Euronext remains a constructive hunting ground for investors: indices are elevated but not euphoric, several blue chips are returning substantial cash to shareholders, and fresh catalysts—from guidance upgrades at UCB to buybacks at Euronext and Danone, and strategic leadership changes at Heineken and Stellantis—are reshaping the opportunity set in real time.

These eight stocks are starting points for deeper research, not a ready‑made portfolio. Before buying any of them, carefully review their most recent annual reports, investor presentations and risk disclosures, and consider how each fits your time horizon, risk tolerance and income needs.